AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Chimeric Therapeutics has made a crucial appointment to its team.
- The company has appointed Dr Jason B. Litten as its Chief Medical Officer.
- Dr Litten, a cell therapy industry leader, holds years of experience in leading drug development.
- He has substantial experience in advancing CAR T cell and NK cell therapies.
Chimeric Therapeutics (ASX:CHM) has made a vital addition to its world-class team of cell therapy pioneers and experts to steer the company’s growth. The Australian leader in cell therapy has appointed Dr Jason B. Litten as its Chief Medical Officer (CMO).
Chimeric is dedicated to developing the most innovative and promising cell therapies for cancer treatment. The company has Chimeric Antigen Receptor (CAR) T therapies and CORE-NK (Natural killer) platform in its clinical pipeline.
Image source: © 2022 Kalkine Media®, CHM website
Who is Dr Litten?
Dr Litten is armed with nearly 15 years of experience in leading drug development. Over the last five years, he has been dedicated to advancing clinical-stage programs in NK and CAR T cell therapies in cancer.
Initially entering the cellular immunotherapy field, Dr Litten has worked on different CAR T and NK cell drug candidates. He has been part of the introductory insight of cell therapies.
Some of his recent positions are as follows:
- Artiva Biotherapeutics (Chief Medical Officer) - Led the development of a portfolio of allogenic Natural Killer (NK) cell therapies
- Juno Therapeutics (Vice President Clinical Development) – Developed and managed the autologous solid tumour CAR T and TCRs cell therapy programs
- Clovis Oncology - Vice President Clinical Development
- Amgen - Medical Director on the Oncology Clinical Development Team
Academic achievements of Dr Litten
- MD from Emory University
- Internship and residency in General Pediatrics - University of Miami
- Fellowship in Pediatric Oncology - University of Texas Southwestern
Ideal addition to Chimeric team
Dr Litten’s vast experience in cell therapy will provide clinical leadership to Chimeric, which is focused on expanding CHM 0201 and 1101 clinical programs and commencing the CHM 2101 clinical program. With his expertise, Chimeric can advance its clinical development rapidly and effectively.
CHM shares were trading at AU$0.130 midday on 26 July 2022.
